CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
COSCIENS Biopharma Inc.
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Mar 25, 2026
$6.49+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $20.66M
- P/E (TTM)
- –
- Dividend yield
- –
COSCIENS Biopharma statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Perfumes, Cosmetics & Other Toilet Preparations companies for comparison
Valuation
| Measure | COSCIENS Biopharma | Industry median |
|---|---|---|
| Market Cap | $20.66M | $163.01M |
| Enterprise Value | $13.35M | $86.72M |
| PS Ratio | 2.76 | 3.58 |
| PB Ratio | 5.38 | 2.02 |
| P/TBV Ratio | 5.38 | 2.30 |
Enterprise value
| Measure | COSCIENS Biopharma | Industry median |
|---|---|---|
| EV / Sales | 1.78 | 2.42 |
Income (trailing twelve months)
| Measure | COSCIENS Biopharma | Industry median |
|---|---|---|
| Revenue | $7.50M | $57.94M |
| Gross Profit | $2.65M | $90.47M |
| Operating Income | -$10.68M | -$21.44M |
| Pretax Income | -$10.35M | -$14.45M |
| EBITDA | -$9.49M | -$16.91M |
Margins
| Measure | COSCIENS Biopharma | Industry median |
|---|---|---|
| Gross Margin | 35.3% | 52.3% |
| Operating Margin | -142.5% | -44.5% |
| Pretax Margin | -138.0% | -13.0% |
| EBITDA Margin | -126.6% | -31.3% |
| FCF Margin | -122.4% | -8.85% |
Returns
| Measure | COSCIENS Biopharma | Industry median |
|---|---|---|
| Return on Capital Employed (ROCE) | -59.9% | -37.8% |
Growth
| Measure | COSCIENS Biopharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -21.8% | 6.01% |
| Revenue Growth (3Y CAGR) | -19.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 15.5% | 6.42% |
Balance sheet
| Measure | COSCIENS Biopharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $7.31M | $62.42M |
| Net Cash (Debt) | $7.31M | $15.68M |
| Net Cash Per Share | $2.30 | $0.66 |
| Equity (Book Value) | $3.84M | $48.79M |
| Book Value Per Share | $1.21 | $1.36 |
| Tangible Book Value | $3.84M | $23.06M |
| Working Capital | $7.89M | $75.77M |
Financial position
| Measure | COSCIENS Biopharma | Industry median |
|---|---|---|
| Current Ratio | 3.18 | 3.30 |
| Quick Ratio | 2.37 | 2.39 |
| Interest Coverage | -63.58 | -7.12 |
Cash flow (trailing twelve months)
| Measure | COSCIENS Biopharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$8.47M | -$12.35M |
| Capital Expenditures | -$706.00K | -$1.06M |
| Free Cash Flow | -$9.18M | -$20.28M |
| FCF Per Share | -$2.88 | -$0.42 |
Efficiency
| Measure | COSCIENS Biopharma | Industry median |
|---|---|---|
| Asset Turnover | 0.27 | 0.38 |
| Inventory Turnover | 2.43 | 2.67 |
| Revenue Per Employee | $267.79K | $398.96K |
| Employee Count | 28 | 74 |
Dividends and yields
| Measure | COSCIENS Biopharma | Industry median |
|---|---|---|
| FCF Yield | -44.4% | -9.15% |
Shares
| Measure | COSCIENS Biopharma | Industry median |
|---|---|---|
| Shares Outstanding | 3,183,330 | 58,179,650 |
| Shares Change (YoY) | 22.6% | 11.1% |
| Float | 2,910,390 | 49,173,100 |
| Shares Held by Insiders | 8.57% | 11.6% |
Scores
| Measure | COSCIENS Biopharma | Industry median |
|---|---|---|
| Altman Z-Score | -1.49 | -0.28 |
| Beneish M-Score | -2.86 | -2.62 |
Calculated by StockData from COSCIENS Biopharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.